KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

2,481
Loading...
Loading...
News
all
press releases
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Zacks·2d ago
News Placeholder
More News
News Placeholder
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
Zacks·5d ago
News Placeholder
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
Zacks·6d ago
News Placeholder
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
Zacks·8d ago
News Placeholder
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Zacks·13d ago
News Placeholder
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Zacks·14d ago
News Placeholder
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Zacks·14d ago
News Placeholder
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
Kiniksa Pharmaceuticals International, plc (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks·14d ago
News Placeholder
Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA?
Court ruling on tariffs fuels market jitters, making low-beta picks like Post, Tencent Music and Kiniksa attractive options.
Zacks·15d ago
News Placeholder
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Zacks·16d ago

Latest KNSA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.